Immuneering Corp — Director's Dealing 2026

Feb 5, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2026-02-03

Reporting Person: Morales Mallory (SVP Finance, CAO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-03	Stock Option	$4.91	A	140000	Acquired	2036-02-03	Class A Common Stock (140000)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.